NDC 85974-133-52

This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.

Requested NDC: 85974-133-52
Product root: 85974-133
Identity scope: Package
Primary current NDC product row: Not present

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
compounder	package	85974-133	85974-133-52	COMPOUNDER	Outsourcing facility compounded drug report	2026-1	2026-09-18
compounder	package	85974-133	85974-133-52	COMPOUNDER	Outsourcing facility compounded drug report	2025-2	2026-09-18

Compounder NDC reports#

Browse the complete compounder directory for this NDC · Browse every current compounder row in the unified auxiliary catalog · browse compounder source captures and parsed snapshots.

Establishment, FEI, Product NDC table
Establishment	FEI	Product NDC	Package NDC	Product	Active ingredients	Reporting period	Normalization
Bennett Pharmaceuticals of America, LLC		85974-133	85974-133-52	tetracaine hcl 4%, bupivacaine hcl 0.5%, phenylephrine hcl 1% gel	40 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL	2026-1	valid
Bennett Pharmaceuticals of America, LLC		85974-133	85974-133-52	tetracaine hcl 4%, bupivacaine hcl 0.5%, phenylephrine hcl 1% gel	40 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL	2025-2	valid

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.